GlassScriptPhysician profile
Murali Alloju
NPI 1194794495
$7,908.25
in general payments reported to CMS, 2019-2025
39 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $286 · 2021: $1,327 · 2022: $1,389 · 2023: $1,230 · 2024: $1,769 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,604 · Education: $46.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,604.36 |
| Education | $46.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,769.54 | 2020-2025 | Rinvoq, Viberzi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,429.84 | 2019-2025 | Entyvio |
| Celgene Corporation | $631.38 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.37 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $406.79 | 2021-2024 | Talicia |
| Janssen Biotech, INC. | $358.61 | 2020-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $306.46 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $291.88 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $246.89 | 2019-2025 | |
| Madrigal Pharmaceuticals | $239.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $173.03 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $166.08 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Lilly USA, LLC | $141.18 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $131.08 | 2021-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $128.16 | 2024-2025 | Voquezna |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,987.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murali Alloju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.